Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atrasentan Abbott.

Peter Norman1

  • 1Norman Consulting, Burnham, Bucks, UK. peter.norman2@btinternet.com

Current Opinion in Investigational Drugs (London, England : 2000)
|September 5, 2002
PubMed
Summary
This summary is machine-generated.

Atrasentan, an endothelin ET(A) receptor antagonist, is in late-stage clinical trials for prostate cancer. Development for hypertension was halted, but cancer trials are advancing, including phase II initiation for multiple cancer types.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The lived experience of depression: a bottom-up review co-written by experts by experience and academics.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2023
Same author

Brexit and UK market exclusivities.

Pharmaceutical patent analyst·2018
Same author

Humira<sup>®</sup>: recent developments.

Pharmaceutical patent analyst·2017
Same author

Enbrel and etanercept biosimilars: a tale of two patent systems.

Pharmaceutical patent analyst·2017
Same author

Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Expert opinion on investigational drugs·2016
Same author

Humira: the impending patent battles over adalimumab biosimilars.

Pharmaceutical patent analyst·2016
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Atrasentan is an investigational drug targeting the endothelin ET(A) receptor.
  • It is being developed by Abbott with potential applications in cancer therapy.

Purpose of the Study:

  • To summarize the development status of Atrasentan, focusing on its clinical trials for various cancers.
  • To note its regulatory status, including Fast Track designation.

Main Methods:

  • Review of clinical trial information and regulatory updates regarding Atrasentan.
  • Phase III trials for prostate cancer.
  • Phase II trials initiated for renal, ovarian, lung, colorectal, breast, and brain cancers.

Main Results:

  • Atrasentan is in Phase III clinical trials for prostate cancer.

Related Experiment Videos

  • Phase II trials for several other cancer types were initiated in July 2002.
  • Development for hypertension was discontinued.

    • Conclusions:

    • Atrasentan shows promise as a potential cancer treatment, particularly for prostate cancer.
    • The drug has received Fast Track status, facilitating regulatory review.
    • Ongoing trials across multiple cancer types indicate continued development efforts.